Who was studied?
Adults with obesity were randomized to retatrutide or placebo.
- Participants
- 338 adults
- Duration
- 48 weeks
- Funding
- Eli Lilly
What did the study find?
Average weight reduction at 48 weeks was 24.2% at 12 mg versus 2.1% with placebo; the primary assessment was at 24 weeks.
What should you keep in mind?
Dose-related gastrointestinal events and a small phase 2 sample limit interpretation.
Why it matters
Promising group averages do not predict an individual outcome.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Published 2023 · PMID 37366315 · DOI 10.1056/NEJMoa2301972
Summary by Peptide Lit, checked against the original abstract on October 7, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.